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One hundred thirty-two patients with biopsy-proven sys•
temic amyloidosis underwent echocardiographic exam•
ination to define the spectrum of cardiac involvement. 
Echocardiographic abnormalities were then correlated 
with clinical variables and survival at follow-up. Patients 
were subgrouped by left ventricular wan thickness: Group 
I, mean wall thickness 12 mm or less; Group II, mean 
wall thickness greater than 12 mm but less than 15 mm; 
Group III, mean wall thickness 15 mm or greater; or 
Group IV, atypical features such as wall motion abnor•
malities or left ventricular dilation. Patients with greater 
wall thickness had a higher frequency of associated echo•
cardiographic abnormalities such as left atrial enlarge-
Cardiac involvement is the most common cause of death in 
patients with primary systemic amyloidosis (1,2). Two•
dimensional echocardiography is a useful method for screen•
ing patients suspected of having cardiac amyloid infiltration 
(3-9). Markedly increased ventricular free wall and septal 
thickness combined with variably depressed systolic func•
tion are typical findings in advanced cases. However, not 
all patients with advanced primary systemic amyloidosis 
(amyloidosis AL) have severe cardiac involvement. In ad•
dition, although previous studies have described a number 
of echocardiographic abnonnalities, investigations have been 
limited by either selection of advanced cases or a relatively 
small number of patients, and quantitation of echocardio•
graphic abnonnalities was not often perfonned. Also, the 
relation between severity of cardiac involvement and sub•
sequent mortality has not been defined. 
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ment or granular sparkling appearance on two-dimen•
sional examination and, more commonly, reduced systolic 
function. The occurrence of clinical congestive heart fail•
ure was strongly correlated with greater wall thickness 
and multiple other echocardiographic abnormalities. 
Survival was negatively influenced both by greater wall 
thickness and reduced systolic function. The median sur•
vival of the entire group was 1.1 years. Echocardio•
graphic examination is an important tool for establishing 
the presence of cardiac amyloid involvement and may 
be useful in estimating prognosis in such patients. 
(J Am Coil CardioI1985;6:737-43) 
The purpose of this investigation was twofold: first, to 
echocardiographically establish in a quantitative fashion the 
spectrum of cardiac involvement in a large group of unse•
lected patients with biopsy-proven amyloidosis AL; and sec•
ond, to relate these findings to subsequent survival. 
Methods 
Patient selection. A list of patients with histologically 
proven amyloidosis AL was obtained by computer search 
and cross-indexed with patients undergoing echocardio•
graphic examination at the Mayo Clinic. The subset of 132 
patients having primary systemic amyloidosis and one or 
more echocardiographic examinations fonned the study 
population. Besides biopsy proof of systemic amyloidosis, 
nearly all patients had an M-protein in serum or urine. In 
14 patients, an endomyocardial biopsy proved the existence 
of cardiac amyloid infiltration. In 28 patients, subsequent 
postmortem study confinned the existence of widespread 
cardiac amyloid involvement. 
Echocardiographic examination. Two-dimensional 
echocardiographic studies were perfonned as described pre•
viously (10). M-mode measurements were perfonned in 
0735-1097/85/$3.30 
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accordance with the American Society of Echocardiography 
guidelines (11) and included the following: left ventricular 
end-diastolic dimension, left ventricular end-systolic di•
mension, diastolic left ventricular free wall thickness, sys•
tolic left ventricular wall thickness, ventricular septal thick•
ness at diastole and systole, left atrial size and aortic root 
dimension. The mean left ventricular wall thickness was 
calculated as one-half the sum of septal and free wall thick•
ness. Left ventricular mass was calculated as reported pre•
viously (12). Percent systolic thickening of the posterior 
wall and ventricular septum were calculated as diastolic 
minus systolic thickness divided by diastolic thickness times 
100%. The ratio of left atrial size to aortic root dimension 
and the radius/thickness ratio (13) were also calculated. Left 
ventricular fractional shortening was calculated as diastolic 
minus systolic left ventricular internal dimension divided 
by diastolic left ventricular internal dimension (14). Results 
of two-dimensional echocardiographic studies were re•
viewed, and the following findings were noted: right ven•
tricular wall thickness, right atrial size and presence or ab•
sence of a granular sparkling appearance, which often occurs 
in patients with advanced cardiac amyloid infiltration. 
Electrocardiography. Total electrocardiographic volt•
age was defined as the sum of the QRS deflections in the 
12 leads with a calibration of 1 mV equal to 10 mm; voltage 
in leads V 1 to V 3 and voltage of the S wave in leads V 1 and 
V6 were also calculated. A mass/voltage ratio was obtained 
as left ventricular mass divided by total voltage. 
Statistical methods. The interrelation among echocar•
diographic variables was analyzed by using linear correla•
tion (15). Two-tailed t tests (16) were used for comparing 
key variables between patients with and without congestive 
heart failure. Kaplan-Meier survival estimation (17) was 
used in the description and examination of time from echo•
cardiographic examination until last follow-up examination 
or death. Associations between survival and patient char-
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acteristics were evaluated using regression based on the Cox 
model (18) for analytic variables and the log-rank test (19) 
for classification variables. 
Results 
Clinical features. The study sample consisted of 132 
patients with histologically proven amyloidosis AL. There 
were 85 men and 47 women. The mean (± SD) age was 
62.5 ± 9.3 years (range 37 to 92). Seventy-five patients 
(57%) had one or more episodes of clinical congestive heart 
failure. Seven patients had sustained hypertension, one had 
calcific aortic stenosis and four patients had known ischemic 
heart disease with angina pectoris or prior myocardial in•
farction. In all patients but one, the diagnosis of amyloidosis 
AL had been made before echocardiographic examination 
(2). 
Subgrouping by wall thickness. The echocardio•
graphic hallmark of cardiac amyloid deposition is increased 
ventricular wall thickness. Therefore, for purposes of anal•
ysis, the study patients were classified into four groups based 
on mean ventricular wall thickness. Table 1 demonstrates 
the various demographic, clinical and echocardiographic 
features of these groups. 
Group I consisted of 34 patients with a mean wall thick•
ness of I2 mm or less. Fifteen (44%) were male, with a 
mean age of 62.2 years. Eight (24%) had prior congestive 
heart failure. Twenty-five (74%) had essentially normal re•
sults on echocardiographic examination as defined by nor•
mal fractional shortening, no granular sparkling, left atrial 
dimension of less than 40 mm and mean left ventricular 
wall thickness of 12 mm or less. In 29 patients who were 
followed up, there were 14 deaths and a median survival 
of 2.4 years (range, 69 days to 3.8 years). Six patients died 
of clearly noncardiac causes (four from renal complications, 
one from acute leukemia and one from gastrointestinal 
Table 1. Primary Systemic Amyloidosis: Echocardiographic and Clinical Variables in Four Subgroups 
Group I Group II Group III Group IV 
MVWT :512 12< MVWT <15 MVWT :2:15 Atypical Total 
Number 34 23 68 7 132 
Age (yr) (mean ± SD) 62.2 ± 11.1 61.4 ± 11.4 62.6 ± 7.7 65.9 ± 8.7 62.5 ± 9.4 
Male 15(44%) 14(61 %) 50(74%) 6(86%) 85(64%) 
CHF 8(24%) 12(52%) 52(80%) 3(43%) 75(58%) 
FS «30%) 0 8(35%) 48(71%) 7(100%) 63(48%) 
LV enlargement (>55 mm) 0 0 0 5(71%) 5(4%) 
GS 0 11(48%) 49(72%) 2(29%) 62(47%) 
LAE 7(21%) 9(41 %) 52(83%) 4(67%) 72(61%) 
Normal echocardiogram 25(74%) 0(0%) 0(0%) 0(0%) 25(19%) 
Deaths/patients followed up 14/29 15/21 43/59 517 77/115 
Median actuarial survival (yr) 2.4 1.3 0.4 0.5 l.l 
CHF = congestive heart failure; FS = fractional shortening; GS = granular sparkling appearance of myocardium; LAE = left atrial enlargement; 
LV = left ventricular; MVWT = mean ventricular wall thickness (in millimeters). Except for age, deaths and survival, the entries are number of patients 
and the percent in the group with the characteristic. 
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bleeding). Six patients died with cardiac complications in•
cluding arrhythmia in one and progressive cardiac deteri•
oration in four. Cause of death was uncertain in two patients. 
Group II consisted of23 patients with a mean wall thick•
ness greater than 12 but less than 15 mm. Fourteen (61%) 
were male, with a mean age of 61.4 years. Twelve (52%) 
had prior congestive heart failure. In eight (35%), fractional 
shortening was reduced below 30%. Eleven (48%) had gran•
ular sparkling, and nine (41 %) had left atrial enlargement. 
In 21 patients who were followed up, there were 15 deaths, 
with a median survival of 1.3 years (range, 20 days to 2.8 
years). All 15 deaths were judged to be the result of cardiac 
complications. Necropsy study in seven patients showed 
widespread cardiac amyloid infiltration. 
Group III consisted of 68 patients with a mean wall 
thickness of 15 mm or greater. Fifty (74%) were male, and 
the mean age was 62.6 years. Fifty-two (80%) had prior 
congestive heart failure, and 48 (71%) had fractional short•
ening reduced below 30%. Forty-nine (72%) had granular 
sparkling on two-dimensional study, and 52 (83%) had left 
atrial enlargement. In 59 patients who were followed up, 
there were 43 deaths, and the median survival was 0.4 year 
(range, 3 days to 4.8 years). The majority (37) of deaths 
were from cardiac causes. Four patients had asymmetric left 
ventricular involvement with a ratio of septal to posterior 
wall thickness of 1.3 or greater. Twenty-five patients had 
cardiac amyloid infiltration proven withh biopsy or at 
necropsy. 
Group IV consists of seven patients with echocardio•
graphic features atypical for amyloid infiltration. Unlike 
Groups I to III (in whom no patient had left ventricular 
enlargement), five patients in Group IV had a diastolic left 
ventricular internal dimension of 55 mm or greater; in the 
other two patients, segmental wall motion abnormalities 
consistent with ischemic heart disease were present. Six of 
the seven patients were male, and the mean age was 65.9 
years. All patients had diminished fractional shortening, and 
two patients had granular sparkling. Four patients had left 
atrial enlargement. All seven patients were followed up, and 
there were five deaths, all from cardiac causes. The median 
survival was 0.5 year (range, 22 days to 2.6 years). Three 
patients had postmortem examination; amyloid deposition 
Table 2. Linear Correlation of Various Echocardiographic Variables 
LVWTd LVM 
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in coronary arteries was seen in all three. Myocardial amy•
loid infiltration was also seen in these patients but to a lesser 
extent. No patient had echocardiographic or autopsy evi•
dence of mural thrombus. 
Interrelation of echocardiographic and clinical vari•
ables. In an attempt to study the relation among echocar•
diographic, electrocardiographic and clinical variables, lin•
ear correlation coefficients were calculated for selected 
measurements (Table 2). Correlations, sample size used for 
analysis and level of statistical significance are shown. Ex•
cept for total voltage, there was a high degree of interrelation 
among the other echocardiographic variables tested. When 
voltage is expressed in ratio to left ventricular mass, the 
resulting variable is also significantly interrelated. Because 
of the high degree of interrelation, individual effects of these 
echocardiographic variables on survival are difficult to 
interpret. 
The occurrence of congestive heart failure is associated 
with reduced survival in amyloidosis AL (20). Table 3 com•
pares clinical and echocardiographic variables in patients 
with and without prior congestive heart failure. Left ven•
tricular wall thickness, mean wall thickness, left ventricular 
mass, left atrial size, fractional shortening, mass/voltage 
ratio and radius/thickness ratio were all significantly dif•
ferent in the two groups. Age, diastolic left ventricular di•
mension, systolic blood pressure and total electrocardio•
graphic voltage were not significantly different. 
Association between variables and survival. Table 4 
demonstrates the association between selected clinical and 
echocardiographic variables and survival. When considered 
singly, highly significant associations with shorter survival 
were found for congestive heart failure, cardiomegaly on 
chest X-ray film, presence of granular sparkling, increased 
mean left ventricular wall thickness, lower fractional short•
ening, left atrial enlargement, lower systolic blood pressure, 
increased mass/voltage ratio, lower radius/thickness ratio, 
increased right ventricular wall thickness and increased left 
ventricular mass. Total voltage, electrocardiographic elec•
trical axis, voltage in leads VI to V3 , and S wave in leads 
V I and V 6 were not significantly associated with survival. 
Modelfor predicting survival. Using Cox's proportional 
hazards regression approach, several models for predicting 
RTH MVWT 
FS -OA75t (l31§) - OA93t (131) OA06t (131) -0.52It (131) 
LA 0.559t (126) 0.625t (125) -O.376t (125) 0.59Jt (126) 
SBP - 0.229* (111) - 0.288t (110) 0.135 (110) - 0.250t (111) 
TV -0.084 (125) 0.032 (124) 0.168 (124) -0.071 (125) 
MVR 0.235* (101) 0.706t (124) -OA7Jt (124) 0.632t (124) 
*Coefficient statistically significantly different from zero at p < 0.05; tcoefficient statistically significantly different from zero at p < 0.01; §number 
of patients with both measurements. FS = fractional shortening; LA = left atrial size; L VM = left ventricular mass; L VWTd = left ventricular diastolic 
wall thickness; MVR = mass/voltage ratio; MVWT = mean diastolic wall thickness; RTH = radius/thickness ratio; SBP = systolic blood pressure; 
TV = total electrocardiographic voltage. 
740 CUETO-GARCIA ET AL. 
AMYLOIDOSIS AND CARDIAC INVOLVEMENT 
JACC Vol. 6, No.4 
October 1985:737-43 
Table 3. Comparison of Selected Variables in Patients With and Without a History of 
Congestive Heart Failure (CHF) 
With CHF 
Variable N Mean SO 
Age (yr) 75 62.9 9.2 
LVWTd (mm) 75 15.3 2.8 
MVWT(mm) 75 15.8 2.9 
LVIDd (mm) 75 41.3 6.1 
LVM (g) 75 318.5 96.0 
LA (mm) 72 43.2 6.3 
SBP (mm Hg) 62 110.4 24.8 
TV (mm) 70 108.6 36.8 
FS (%) 75 26.0 8.7 
MVR (mmlmm) 70 3.19 1.43 
RTH (mmlmm) 75 1.38 0.45 
Abbreviations as in Table 2. 
survival were generated. First, we developed a model that 
included the following clinical and electrocardiographic 
measures: cardiomegaly, congestive heart failure, systolic 
blood pressure, electrical axis, total voltage, voltage in leads 
VI to V3 , and voltage of the S wave in leads VI and V6 . 
Next, we determined which of the echocardiographic vari•
ables added significantly to our prediction model, which 
included all the clinical and electrocardiographic measures 
described. The echocardiographic variables that added sig•
nificantly were radius/thickness ratio (p = 0.012), left ven•
tricular mass (p = 0.048) and mean left ventricular wall 
thickness (p = 0.010). When anyone of the three echo•
cardiographic measures was included in the model, neither 
of the other two measures added significantly to the pre•
diction of subsequent survival. In the second series of models, 
we first included all eight echocardiographic measures (frac•
tional shortening, left atrial enlargement, mass/voltage ratio, 
radius/thickness ratio, left ventricular mass, mean left ven•
tricular wall thickness and ratio of left atrial to aortic root 
size). Then we determined which clinical and electrocar•
diographic measures significantly added to the prediction of 
survival. Electrocardiographic axis (p < 0.00 I), cardio•
megaly (p = 0.001), congestive heart failure (p = 0.007) 
and systolic blood pressure (p = 0.012) were all individ•
ually significantly associated with survival when considered 
simultaneously with the eight echocardiographic measures. 
In addition, when the eight echocardiographic measure•
ments were considered simultaneously with axis, cardio•
megaly, congestive heart failure and systolic blood pressure, 
each of the four clinical measures added significantly (p :s 
0.01) to the model. In summary, both echocardiographic 
variables and clinical variables act additively in terms of 
predicting survival in these multivariate models. 
Fractional shortening and mean left ventricular wall 
thickness. These two echocardiographic variables measure 
distinctly different myocardial abnormalities. Fractional 
Without CHF 
t Test 
N Mean SO p Value 
54 61.4 9.5 >0.10 
54 12.3 2.7 <0.001 
54 12.3 2.8 <0.001 
53 43.7 6.1 <0.030 
53 234.5 79.2 <0.001 
53 36.0 7.0 <0.001 
49 124.6 20.4 <0.002 
53 117.2 28.8 >0.10 
53 36.5 8.9 <0.001 
52 2.07 0.82 <0.001 
53 1.88 0.54 <0.001 
shortening, like ejection fraction, is a measure of systolic 
left ventricular performance; the latter is strongly related to 
survival in other forms of heart disease (21). Mean left 
ventricular wall thickness corresponds to the severity of 
amyloid infiltration and would be expected to adversely 
influence diastolic left ventricular properties such as com•
pliance. Therefore, it seemed logical to focus attention on 
these two variables in relation to survival. Figure 1 shows 
survival after echocardiographic examination for various 
combinations of mean left ventricular wall thickness and 
fractional shortening. For patients with normal fractional 
shortening, a trend for poorer survival with increasing mean 
wall thickness can be seen (p = 0.055, top three curves). 
Similarly, for Group III patients with a mean wall thickness 
of 15 mm or greater, there is evidence for reduced survival 
as fractional shortening decreases (p = 0.010, bottom three 
curves). 
Comment 
Echocardiographic findings in cardiac amyloidosis and 
role in prognosis. In 1976, Child et al. (3) first described 
the echocardiographic findings in patients with cardiac amy•
loid infiltration. Other investigations (4-9) subsequently 
confirmed the findings of thick ventricular walls, small ven•
tricular chambers, dilated atria, granular sparkling appear•
ance and often depressed left ventricular systolic function 
that characterize the advanced stage of this disease. Our 
study is the first to demonstrate the wide spectrum of echo•
cardiographic findings in patients with histologically proven 
amyloidosis AL. Nineteen percent of our study group had 
essentially normal results on echocardiography as defined 
by fractional shortening greater than 30%, normal left atrial 
size, mean left ventricular wall thickness of 12 mm or less 
and absence of granular sparkling on two-dimensional ex•
amination. Furthermore, separation of the patients into Groups 
Table 4. Association Between Survival and Cardiac Variables 
Deaths p Value 
Cox Regression 
Log-Rank on Continuous 
Variable N Observed Expected* Test Variable 
MVWT(mm) 
oS 12 27 12 28.7 <0.001 <0.001 
13-14 22 16 15.2 
~15 60 44 28.1 
FS (%) 
<20 27 25 8.4 <0.001 <0.001 
20-29 34 24 20.0 
dO 54 28 48.6 
LA (mm) 
30-39 41 24 35.5 0.002 <0.001 
40-49 44 30 26.3 
~50 19 16 8.2 
RTH (mm/mm) 
< 1.5 64 46 33.3 0.004 <0.001 
1.5-1.9 23 17 17.4 
~2 28 14 26.4 
LVM (g) 
~300 46 34 22.7 <0.001 <0.001 
250-299 16 13 8.0 
<250 53 30 46.3 
MVR (mm/mm) 
~3 34 24 16.2 0.001 <0.001 
2.0-2.9 38 28 20.8 
<2 37 19 34.0 
RVWT(mm) 
<7 41 29 39.7 0.003 <0.001 
~7 41 31 20.3 
Granular sparkling 
Yes 54 41 23.7 <0.001 NA 
No 62 36 53.3 
Congestive heart failure 
Yes 71 59 35.9 <0.001 NA 
No 44 18 41.1 
Heart enlargement on X-ray 
Yes 38 33 15.7 <0.001 NA 
No 73 41 58.3 
SBP 
<100 25 22 11.4 <0.001 <0.001 
100-119 27 23 16.3 
~120 49 24 41.3 
TV (mm) 
<90 37 29 22.8 0.262 0.078 
90-119 34 17 21.0 
~120 39 25 27.2 
Axis (0) 
~90 12 10 5.1 0.073 0.232 
0-89 60 35 39.1 
<0 39 27 27.8 
Voltage V I-V3 (mm) 
<10 14 II 6.6 0.004 0.022 
10-14 39 30 21.2 
~15 56 30 43.2 
Voltage S I V6 (mm) 
<10 23 19 12.2 0.017 0.026 
10-14 32 23 18.5 
~15 55 29 40.3 
*Expected deaths are calculated as in the log-rank situation assuming that the risk of death at any particular 
time is the same in the groups being compared. They reflect the relative number of patients being followed at 
any point in time. They are not based on survival as experienced in a general geographic population. NA = 
not applicable; RVWT = right ventricular wall thickness; other abbreviations as in Table 2. 
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(%) 12 < MVWT < 15 
FS ~ 30 (n= 13) 
Figure 1. Survival of patients with various 
combinations of mean left ventricular wall 
thickness (MVWT) and fractional shortening 
(FS) from the time of echocardiographic ex•
amination. The top three curves show sur•
vival in patients with increasing wall thickness 
and normal fractional shortening. The lower 
two curves show survival of patients with 
moderate and severe reduction of fractional 
shortening. 
MVWT ~15 
25 FS ~ 30 (n=13) 
MVWT ~15 




I to III based on increasing mean wall thickness showed 
that as wall thickness increases, clinical, electrocardio•
graphic and other echocardiographic abnormalities become 
more frequent. Thus, in Group I, with a mean wall thickness 
of 12 mm or less, 74% of patients had what would be 
considered normal results on echocardiographic examina•
tion. Only 21 % had left atrial enlargement, and only 24% 
had symptoms of congestive heart failure. No patient had 
reduced fractional shortening or granular sparkling. In pa•
tients with moderate increase in wall thickness (13 to 14 
mm), 48% had granular sparkling appearance. Forty-one 
percent had left atrial enlargement, and 35% had reduced 
fractional shortening. In the group with a mean wall thick•
ness of 15 mm or greater, 83% had left atrial enlargement, 
and 71% had reduced fractional shortening. Asymmetric 
left ventricular thickening occurred in 3% of patients, less 
frequently than previously reported (22). 
Not only was congestive heart failure increasingly com•
mon as wall thickness increased, but statistically significant 
differences in virtually all echocardiographic variables were 
present when comparing patients with and without conges•
tive failure. An increase in right ventricular wall thickness 
without increased left ventricular wall thickness was ob•
served in only one patient. Median survival was inversely 
related to wall thickness with the longest survival in Group 
I (2.4 years) and the shortest survival in Group III (0.4 
year). Using the two echocardiographic variables, fractional 
shortening and mean left ventricular wall thickness, it was 
possible to construct actl.!arial survival curves as shown in 
Figure I. An incremental effect on survival of increasing 
wall thickness with normal fractional shortening and de•
creasing fractional shortening with large wall thickness was 
observed. These findings help predict survival from echo•
cardiographic examination in patients with primary systemic 
amyloidosis. 
Rate of progression on echocardiogram. The rate of 
progression of disease assessed eChocardiographically was 
also important in survival as reported previously (23). In 
3 
the subgroup of 27 paitents who had serial echocardio•
graphic examinations, clinical cardiac deterioration was highly 
associated with progression of cardiac amyloid involvement. 
Whereas patients without deterioration showed only mild 
increase in left ventricular mass, those with deterioration 
showed mean increases in wall thickness of 34%, left ven•
tricular mass of 42%, right ventricular wall thickness of 
78% and mass/voltage ratio of 68%. The strong relation 
between worsening of clinical status (primarily congestive 
heart failure) and these echocardiographic variables of amy•
loid infiltration is directly in keeping with our current study 
(Table 3). 
Atypical features in Group IV. The seven patients in 
Group IV with atypical features deserve comment. Five of 
the seven patients in this group had left ventricular enlarge•
ment, whereas none of the patients in Groups I to III did. 
Two had wall motion abnormalities consistent with prior 
ischemic damage. At necropsy study in three patients, amy•
loid infiltration of the coronary arteries was present. (Two 
of these patients also had significant atherosclerotic coronary 
artery disease.) Whether the remaining four patients in this 
group had cardiac amyloid involvement remains uncertain. 
This atypical group represents only 5% of the total. Thus, 
the finding of left ventricular dilation is a rare occurrence 
in myocardial amyloid infiltration, though it may conceiv•
ably be related to coronary artery involvement. 
Limitations. One limitation of this investigation is the 
lack of biopsy or necropsy proof of cardiac infiltration in 
every patient. Thus, in patients with increased wall thickness 
who did not undergo biopsy or postmortem examination, it 
is impossible to conclusively prove the presence of cardiac 
amyloid infiltration. However, among those who did undergo 
histologic review, all patients in Group II or III were found 
to have cardiac amyloid infiltration at postmortem or biopsy. 
Summary. A spectrum of cardiac abnormalities exists 
in patients with primary systemic amyloidosis. Nineteen 
percent of the patients studied had normal results on echo•
cardiographic examination. With mild involvement, there 
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is a modest increase in left ventricular wall thickness with 
a tendency toward preservation of systolic function. With 
more severe involvement, there is a marked increase in 
ventricular wall thickness and late deterioration of systolic 
function. The presence of one or more episodes of conges•
tive heart failure correlates highly with more advanced de•
grees of abnormalities in multiple echocardiographic vari•
ables. Although there is some interrelation among 
echocardiographic variables tested, two easily measured 
variables-mean left ventricular wall thickness and frac•
tional shortening-appear to simultaneously contribute to 
the prediction of survival. Multivariate analysis shows that 
both clinical and echocardiographic variables exert additive 
effects on survival. M-mode and two-dimensional echocar•
diographic examination is an important tool for establishing 
the presence of cardiac amyloid infiltration and may be 
useful in estimating prognosis in such patients. 
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